Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials

Overview

Journal Children (Basel)

Specialty Health Services

Date 2021 Apr 30

PMID 33922085

Citations 5

Authors

Bibhuti B Das

William B Moskowitz

Javed Butler

Affiliations

Soon will be listed here.

Abstract

This review discusses the potential drug and device therapies for pediatric heart failure (HF) due to reduced systolic function. It is important to realize that most drugs that are used in pediatric HF are extrapolated from adult cardiology practices or consensus guidelines based on expert opinion rather than on evidence from controlled clinical trials. It is difficult to conclude whether the drugs that are well established in adult HF trials are also beneficial for children because of tremendous heterogeneity in the mechanism of HF in children and variations in the pharmacokinetics and pharmacodynamics of drugs from birth to adolescence. The lessons learned from adult trials can guide pediatric cardiologists to design clinical trials of the newer drugs that are in the pipeline to study their efficacy and safety in children with HF. This papers focus is that the reader should specifically think through the pathophysiological mechanism of HF and the mode of action of drugs for the selection of appropriate pharmacotherapy. We review the drug and device trials in adults with HF to highlight the knowledge gap that exists in the pediatric HF population.

Citing Articles

Relationship between Baseline Serum Potassium and 1-Year Readmission in Pediatric Patients with Heart Failure: A Retrospective Cohort Study.

Han Y, Huang Y, Su D, Liu D, Chen C, Pang Y Children (Basel). 2024; 11(6).

PMID: 38929304 PMC: 11201687. DOI: 10.3390/children11060725.

A Review of the Mechanism of Action of Drugs Used in Congestive Heart Failure in Pediatrics.

Singh 4th R, Meshram R, Tiwari A Cureus. 2023; 15(1):e33811.

PMID: 36819391 PMC: 9931378. DOI: 10.7759/cureus.33811.

Diagnosis and Management of Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Children.

Hegazy M, Ghaleb S, Das B Children (Basel). 2023; 10(1).

PMID: 36670699 PMC: 9856743. DOI: 10.3390/children10010149.

Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial.

Shaddy R, Burch M, Kantor P, Solar-Yohay S, Garito T, Zhang S Circ Heart Fail. 2023; 16(3):e009816.

PMID: 36601956 PMC: 10022669. DOI: 10.1161/CIRCHEARTFAILURE.122.009816.

Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics.

Varela-Chinchilla C, Sanchez-Mejia D, Trinidad-Calderon P J Cardiovasc Dev Dis. 2022; 9(7).

PMID: 35877563 PMC: 9316572. DOI: 10.3390/jcdd9070201.

References

Sagawa T, Sagawa K, Kelly J, Tsushima R, Wasserstrom J . Activation of cardiac ryanodine receptors by cardiac glycosides. Am J Physiol Heart Circ Physiol. 2002; 282(3):H1118-26. DOI: 10.1152/ajpheart.00700.2001. View

Abraham W, Cheng M, Smoluk G . Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers. Congest Heart Fail. 2005; 11(2):59-64. DOI: 10.1111/j.1527-5299.2005.03792.x. View

Psotka M, Gottlieb S, Francis G, Allen L, Teerlink J, Adams Jr K . Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 73(18):2345-2353. DOI: 10.1016/j.jacc.2019.02.051. View

Packer M, Fowler M, Roecker E, Coats A, Katus H, Krum H . Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002; 106(17):2194-9. DOI: 10.1161/01.cir.0000035653.72855.bf. View

Follath F, Cleland J, Just H, Papp J, Scholz H, Peuhkurinen K . Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360(9328):196-202. DOI: 10.1016/s0140-6736(02)09455-2. View

Packer M, Colucci W, Fisher L, Massie B, Teerlink J, Young J . Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2014; 1(2):103-11. DOI: 10.1016/j.jchf.2012.12.004. View

Regen R, Gonzalez A, Zawodniak K, Leonard D, Quigley R, Barnes A . Tolvaptan increases serum sodium in pediatric patients with heart failure. Pediatr Cardiol. 2013; 34(6):1463-8. DOI: 10.1007/s00246-013-0671-y. View

Macicek S, Macias C, Jefferies J, Kim J, Price J . Acute heart failure syndromes in the pediatric emergency department. Pediatrics. 2009; 124(5):e898-904. DOI: 10.1542/peds.2008-2198. View

Das B . Plasma B-type natriuretic peptides in children with cardiovascular diseases. Pediatr Cardiol. 2010; 31(8):1135-45. DOI: 10.1007/s00246-010-9758-x. View

10.

Uretsky B, Young J, Shahidi F, Yellen L, Harrison M, Jolly M . Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993; 22(4):955-62. DOI: 10.1016/0735-1097(93)90403-n. View

11.

Desai A, McMurray J, Packer M, Swedberg K, Rouleau J, Chen F . Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015; 36(30):1990-7. DOI: 10.1093/eurheartj/ehv186. View

12.

Fox K, Komajda M, Ford I, Robertson M, Bohm M, Borer J . Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013; 34(29):2263-70. DOI: 10.1093/eurheartj/eht101. View

13.

Di Candia A, Castaldi B, Bordin G, Cerutti A, Reffo E, Biffanti R . Pulmonary Artery Banding for Ventricular Rehabilitation in Infants With Dilated Cardiomyopathy: Early Results in a Single-Center Experience. Front Pediatr. 2020; 8:347. PMC: 7381108. DOI: 10.3389/fped.2020.00347. View

14.

Das B, Koch J, Dimas V, Guleserian K, Nugent A . Use of nesiritide in critically ill children with biventricular dysfunction suffering from oliguria despite standard heart-failure management. Cardiol Young. 2015; 26(4):819-23. DOI: 10.1017/S1047951115002590. View

15.

Schranz D, Recla S, Malcic I, Kerst G, Mini N, Akintuerk H . Pulmonary artery banding in dilative cardiomyopathy of young children: review and protocol based on the current knowledge. Transl Pediatr. 2019; 8(2):151-160. PMC: 6514280. DOI: 10.21037/tp.2019.04.09. View

16.

Wang A, Cui C, Fan Y, Zi J, Zhang J, Wang G . Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial. Crit Care. 2020; 23(1):428. PMC: 6937718. DOI: 10.1186/s13054-019-2704-2. View

17.

Packer M, Anker S, Butler J, Filippatos G, Ferreira J, Pocock S . Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2020; 143(4):326-336. PMC: 7834905. DOI: 10.1161/CIRCULATIONAHA.120.051783. View

18.

Packer M, Gheorghiade M, Young J, Costantini P, Adams K, Cody R . Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993; 329(1):1-7. DOI: 10.1056/NEJM199307013290101. View

19.

Lechner E, Hofer A, Leitner-Peneder G, Freynschlag R, Mair R, Weinzettel R . Levosimendan versus milrinone in neonates and infants after corrective open-heart surgery: a pilot study. Pediatr Crit Care Med. 2012; 13(5):542-8. DOI: 10.1097/PCC.0b013e3182455571. View

20.

Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M, Willnow T . Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci. 2002; 71(23):2701-12. DOI: 10.1016/s0024-3205(02)01990-2. View